Search Results

You are looking at 1 - 1 of 1 items for :

  • Author or Editor: Abbie L. Speas x
  • Bone, Joint, and Cartilage x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To examine the ability of preemptive administration of a proprietary neurokinin-1 (NK1) receptor antagonist to attenuate limb dysfunction associated with monosodium urate–induced synovitis in the stifle joints of dogs.

Animals—16 clinically normal adult mixed-breed dogs (8 males and 8 females).

Procedures—A crossover study was conducted in 2 phases. Dogs were assigned to 2 groups (8 dogs/group) and orally administered an NK1 receptor antagonist (3 mg/kg) or a control substance once daily for 4 days. Synovitis was then induced in the left stifle joint by intra-articular injection of monosodium urate. Investigators were not aware of treatment group assignments. Dogs were evaluated by use of subjective lameness scores during standing, walking, and trotting and by use of ground reaction force data 3, 6, 9, 12, and 24 hours after urate injection. After a 21-day washout period, the experiment was repeated with each dog administered the other treatment and injected with monosodium urate in the contralateral stifle joint.

Results—No significant differences were detected between the NK1 receptor antagonist and control treatments with regard to peak vertical force, vertical impulse area, or subjective evaluations of lameness during standing, walking, or trotting, except during walking 24 hours after monosodium urate injection.

Conclusions and Clinical Relevance—Preemptive administration of an NK1 receptor antagonist failed to significantly improve subjective or objective outcome measures in dogs with monosodium urate–induced synovitis.

Full access
in American Journal of Veterinary Research